These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33148404)

  • 21. In situ forming risperidone implants: Effect of PLGA attributes on product performance.
    Wang X; Bao Q; Wang R; Kwok O; Maurus K; Wang Y; Qin B; Burgess DJ
    J Control Release; 2023 Sep; 361():777-791. PubMed ID: 37591464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo characterization of Perseris and compositionally equivalent formulations.
    Wang X; Bao Q; Wang R; Li T; Wang Y; Qin B; Li Q; Burgess DJ
    Int J Pharm; 2023 Jul; 642():123170. PubMed ID: 37354927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manufacturing dexamethasone intravitreal implants: Process control and critical quality attributes.
    Costello MA; Liu J; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
    Int J Pharm; 2023 Nov; 647():123515. PubMed ID: 37844672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of branched poly(lactide-co-glycolide) polymers used in injectable, long-acting formulations.
    Hadar J; Skidmore S; Garner J; Park H; Park K; Wang Y; Qin B; Jiang X
    J Control Release; 2019 Jun; 304():75-89. PubMed ID: 31054992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells.
    Intra J; Salem AK
    J Drug Target; 2011 Jul; 19(6):393-408. PubMed ID: 20681752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of structural relaxation on the preparation and drug release behavior of poly(lactic-co-glycolic)acid microparticle drug delivery systems.
    Allison SD
    J Pharm Sci; 2008 Jun; 97(6):2022-35. PubMed ID: 17828755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of implant formation on drug release kinetics of in situ forming implants.
    Suh MS; Kastellorizios M; Tipnis N; Zou Y; Wang Y; Choi S; Burgess DJ
    Int J Pharm; 2021 Jan; 592():120105. PubMed ID: 33232755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA's Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes.
    Wang Y; Qin B; Xia G; Choi SH
    AAPS J; 2021 Jun; 23(4):92. PubMed ID: 34189655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of PLGA molecular weight distribution on leuprolide release from microspheres.
    Ochi M; Wan B; Bao Q; Burgess DJ
    Int J Pharm; 2021 Apr; 599():120450. PubMed ID: 33675924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
    Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
    Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
    Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
    J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
    Rafiei P; Haddadi A
    Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microparticles produced by the hydrogel template method for sustained drug delivery.
    Lu Y; Sturek M; Park K
    Int J Pharm; 2014 Jan; 461(1-2):258-69. PubMed ID: 24333903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
    Mehta AK; Yadav KS; Sawant KK
    Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictability of drug encapsulation and release from propylene carbonate/PLGA microparticles.
    Grizić D; Lamprecht A
    Int J Pharm; 2020 Aug; 586():119601. PubMed ID: 32622807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables.
    Meeus J; Scurr DJ; Appeltans B; Amssoms K; Annaert P; Davies MC; Roberts CJ; Van den Mooter G
    Eur J Pharm Biopharm; 2015 Feb; 90():22-9. PubMed ID: 25448071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
    Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
    J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose.
    Sharifi F; Meqbil YJ; Otte A; Gutridge AM; Blaine AT; van Rijn RM; Park K
    Pharm Res; 2021 Jul; 38(7):1221-1234. PubMed ID: 34114163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosol Derived Poly(ester-arylate)s for Sustained Drug Delivery from Microparticles.
    Miles CE; Gwin C; Zubris KAV; Gormley AJ; Kohn J
    ACS Biomater Sci Eng; 2021 Jun; 7(6):2580-2591. PubMed ID: 34010557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Method matters: Development of characterization techniques for branched and glucose-poly(lactide-co-glycolide) polymers.
    Hadar J; Skidmore S; Garner J; Park H; Park K; Wang Y; Qin B; Jiang XJ; Kozak D
    J Control Release; 2020 Apr; 320():484-494. PubMed ID: 32027937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.